We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Metabolites Pattern Distinguishes Myasthenia Gravis from RA Patients

By LabMedica International staff writers
Posted on 09 Sep 2019
A team of Canadian researchers used a pattern of 12 metabolites to distinguish myasthenia gravis patients from healthy individuals or from those with rheumatoid arthritis.

Myasthenia gravis (MG) is an autoimmune disease caused by antibodies that block or destroy nicotinic acetylcholine receptors at the junction between the nerve and muscle. More...
This prevents nerve impulses from triggering muscle contractions. MG, which affects approximately one in 5,000 people, most often women under age 40 or men over 60, is a chronic neuromuscular disease that leads to varying degrees of skeletal muscle weakness. The most commonly affected muscles are those of the eyes, face, and swallowing. It can cause double vision, drooping eyelids, trouble talking, and trouble walking. Left untreated, MG symptoms may cause significant morbidity or even death.

To date, no robust biological marker is available to follow the course of the disease. Therefore, new diagnostic approaches and biological markers are essential not only for improved diagnosis of the disease except for improved outcomes.

In this regard, investigators at the University of Alberta Faculty of Medicine & Dentistry (Edmonton, Canada) performed metabolic analyses using acid- and dansyl-labelled serum from 46 seropositive MG patients, 23 rheumatoid arthritis (RA) patients, and 49 healthy controls.

Results revealed that after identifying more than 10,000 compounds in the serum samples, the investigators were able to point to a unique pattern of 12 metabolites exclusive to patients with myasthenia gravis.

"This is really important because now we have a way to easily separate a patient with myasthenia gravis from someone with rheumatoid arthritis or another autoimmune disease," said contributing author Dr. Zaeem Siddiqi, professor of neurology at the University of Alberta Faculty of Medicine & Dentistry. "What is more, now we are able to explore how those 12 metabolites change in mild, moderate, or severe cases so we can make this biomarker more robust and more effective for predicting the course of the disease and developing treatment plans. Now we have a unique fingerprint or map of metabolites that can easily separate healthy individuals from those with myasthenia gravis, and a path to the discovery of more accurate and specific treatments."

The myasthenia gravis paper was published in the August 1, 2019, online edition of the journal Metabolomics.

Related Links:
University of Alberta Faculty of Medicine & Dentistry


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New evidence now questions whether a single stool-test cutoff should be applied uniformly across all age groups.(Photo courtesy of Paul Maguire - Adobe Stock)

Study Questions Uniform Stool-Test Cutoff Across Age Groups

Colorectal cancer remains a major clinical challenge, ranking as the fourth most common cancer and the second-leading cause of cancer death in the U.K. Early-onset colorectal cancer, defined as diagnosis... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image

Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil

Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.